Medicine and Dentistry
Patient
100%
Dextromethorphan
62%
Levodopa
50%
Complication
37%
Dyskinesia
25%
Unified Parkinson's Disease Rating Scale
25%
Inpatient
25%
Arm
25%
Activities of Daily Living
25%
Side Effect
12%
Parkinson's Disease
12%
Chemotherapeutic Agent
12%
Drug
12%
NMDA Receptor
12%
NMDA Receptor Antagonist
12%
Amaurosis
12%
Drowsiness
12%
Nursing and Health Professions
Dextromethorphan
62%
Levodopa
50%
Complication
37%
Dyskinesia
25%
Unified Parkinson Disease Rating Scale
25%
Dose
25%
Physician
12%
Side Effect
12%
Drug
12%
Therapeutic Window
12%
Parkinson Disease
12%
Blindness
12%
N Methyl Dextro Aspartic Acid Receptor
12%
Placebo
12%
N Methyl Dextro Aspartic Acid Receptor Blocking Agent
12%
Drowsiness
12%
INIS
motors
75%
patients
62%
nervous system diseases
37%
doses
25%
fluctuations
25%
drugs
12%
range
12%
transmission
12%
receptors
12%
side effects
12%
Pharmacology, Toxicology and Pharmaceutical Science
Dextromethorphan
62%
Levodopa
50%
Complication
37%
Dyskinesia
25%
Side Effect
12%
Parkinson Disease
12%
N Methyl Dextro Aspartic Acid Receptor
12%
Drug
12%
N Methyl Dextro Aspartic Acid Receptor Blocking Agent
12%
Blindness
12%
Drowsiness
12%
Neuroscience
Dextromethorphan
62%
L-DOPA
50%
Parkinson's Disease
37%
Dyskinesia
25%
N-Methyl-D-Aspartic Acid
12%
NMDA Receptor
12%
Crossover Study
12%
Placebo
12%
Drowsiness
12%